Investor jitters about cardiac side effects were quelled and full approval chances bolstered by interim phase III data from Amgen Inc.'s trial testing the second-generation proteasome inhibitor Kyprolis (carfilzomib) when combined with Revlimid (lenalidomide, Celgene Corp.) and low-dose dexamethasone against relapsed multiple myeloma (MM).